Article Text

PDF

Interactions of L-dopa and amantadine in patients with Parkinsonism
  1. B. Cox,
  2. G. Danta1,
  3. H. Schnieden,
  4. G. M. Yuill
  1. Department of Neurology, Manchester Royal Infirmary, University of Manchester
  2. The Department of Pharmacology, University of Manchester

    Abstract

    Twenty-seven patients with Parkinson's disease participated in a double-blind crossover trial of L-dopa and amantadine. Each drug was given for six weeks, and six weeks were allowed to elapse between the two periods of treatment. Marked improvement occurred in patients given L-dopa first, whereas no clinical effect was observed in those patients treated first with amantadine. L-dopa was less beneficial to patients who had previously received amantadine, whereas amantadine became effective in patients who had previously taken L-dopa. The effect of pre-treatment with one drug on the therapeutic effectiveness of the other drug is reflected in changes of homovanillic acid levels in the cerebrospinal fluid.

    Statistics from Altmetric.com

    Footnotes

    • 1 Requests for reprints: Department of Neurology, North Staffordshire Royal Infirmary, Stoke-on-Trent.

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.